32.7 C
Vientiane
Monday, June 30, 2025
spot_img
Home Blog Page 330

MyRepublic Launches Singapore’s First Insurance Tailored for Geeks and Collectors


SINGAPORE – Media OutReach Newswire – 28 April 2025 – MyRepublic, an award-winning fibre broadband service provider in Singapore, has launched Geek Insurance, a first-of-its-kind insurance product designed specifically for hobbyists, gamers, and collectors. This initiative, developed in collaboration with HL Assurance, addresses the growing demand for specialised protection of high-value collectibles and gaming equipment.

MyRepublic Geek Insurance
MyRepublic Geek Insurance

As interest in trading card games, figurines, and collectible merchandise continues to rise in Singapore, many enthusiasts are investing significantly in their collections. However, traditional home insurance policies often provide limited or no coverage for such items.

Geek Insurance offers a dedicated solution, focusing on coverage for collectibles, personal electronic devices, and other household contents in the home against loss, theft, and accidental damage.

Items eligible for coverage under Geek Insurance include:

  • Trading Card Games (TCGs)
  • Figurines and Toys
  • Game Collections
  • Comic Books
  • Limited-Edition Merchandise
  • Memorabilia

“At MyRepublic, we’ve long embraced geek and gamer culture as part of our brand identity. Geek Insurance is a natural extension of that commitment, offering collectors peace of mind through targeted protection,” said Lawrence Chan, Managing Director and Chief AI Officer, MyRepublic Broadband. “We recognise the value — both financial and sentimental — that collectors place on their items and aim to provide insurance that meets those unique needs. Our own team is passionate about trading card games and collectibles too, so this is something that’s close to our hearts.”

“We are proud to partner with MyRepublic to underwrite Geek Insurance and bring this innovative product to life,” said Kelvin Lim, CEO, HL Assurance. “We understand the deep passion collectors have for their hobbies, and we’ve designed this product to offer the protection and peace of mind they deserve. This collaboration allows us to address a previously underserved segment in a meaningful and innovative way.”

Geek Insurance reflects MyRepublic’s continued dedication to developing innovative solutions for niche communities. The plans, starting from $4.90 per month with up to $15,000 coverage, feature a simplified claims process, competitive premiums, and tailored benefits, empowering customers to enjoy their hobbies without the burden of potential loss or damage. The launch of Geek Insurance marks another milestone in MyRepublic’s ongoing pursuit to deliver differentiated value and service innovation.
In addition to Geek Insurance, MyRepublic is preparing to introduce a comprehensive home insurance plan aimed at individuals seeking broader coverage for their residences and personal property.

For more information on Geek Insurance and how to apply, please visit https://myrepublic.net/sg/geek-insurance/ or contact the media representative below.

Hashtag: #GeekInsurance #GeekInsurance #GeeksUseUs #GeekCulture #CardCollectors





The issuer is solely responsible for the content of this announcement.

MyRepublic Broadband Pte Ltd

MyRepublic is an award-winning telecom operator whose values lie in the future of connectivity, the next opportunity to disrupt, and innovations that will make a real difference. The provider’s priority is to redefine broadband and mobile connectivity in the markets it operates and empower customers to understand what a true modern connectivity experience can be.

Fair Home: Valued Effort: Pairwork App Launches in the US to Quantify Housework

TOKYO, April 28, 2025 /PRNewswire/ — (HQ: Shinagawa-ku, Tokyo; President & CEO: Toshikazu Saito; hereinafter “mediba”), a group company of KDDI Corporation (Japanese major telecommunication company), will begin offering its “Pairwork” app to the U.S. market on April 24, 2025, marking the start of its full-scale global expansion.

Pairwork app helps couples visualize and share housework chores
Pairwork app helps couples visualize and share housework chores

Pairwork has been helping working couples divide housework chores by visualizing who did what chores, when, and how much effort was involved. With its entry into the U.S. market, the company is now moving forward with full-scale global expansion, aiming to support diverse work styles and help couples balance their work and family lives.

Background of U.S. Expansion

In the U.S., approximately 60% of families with children are dual-income, and this figure is said to be over 50%, especially for families with children under 6. As the number of dual-income housework increases, the need to clarify and efficiently share housework responsibilities grows year by year. We believe Pairwork will meet the needs of U.S. dual-income housework by providing an environment where couples can easily cooperate and visualize housework tasks and chore-sharing status on smartphones and tablets.

In particular, we expect the “hourly wage simulation function” in Pairwork to be a unique selling point in the U.S. market and offer a new standard for evaluating housework.  By comparing hourly wage equivalents of housework internationally using our data, we strive to cultivate a global understanding of the importance of shared housework, fostering a worldwide awareness of the value inherent in domestic labor.

Key Features of Pairwork app

1. Visualize and share housework chores

Various housework chores can be easily shared through the app. Clarifying chore details and increasing transparency enables a more detailed division of responsibilities, fostering a cooperative relationship between partners.

2. Easy registration of chores by simply selecting from a list of chores

You can easily register chores by simply selecting the appropriate item from the list in the app. The simple yet comprehensive list helps users record chores they might not normally notice. In addition, since new chores can be added and the list can be freely edited, each housework can create its own unique list of chores.

3. Visualization of effort status and time

The app provides a clear visual display of who did which chores and for how long. This makes it easy to see which chores are completed and identify any uneven distribution of responsibilities.

4. Visualization of contribution by setting hourly wage for labor value

The monetary value of housework, agreed upon by the couple, can be set as an hourly rate, allowing the app to display each partner’s share of housework. This clearly shows the time and effort each partner invests in housework, fostering mutual appreciation and active cooperation.

App Name

Pairwork

usage fee

Free (*Premium membership: US$4.99 /month)

Download

App Store: https://apps.apple.com/app/id6464381260 

Google Play: https://play.google.com/store/apps/details?id=jp.mediba.pairwork 

Supported
models

iOS 11.0 or higher (smartphones) Android 7.0 or higher (smartphones)

Using the U.S. launch of Pairwork as a foothold, mediba will support working couples around the world to balance work and family and create a prosperous future together.

  • About “Pairwork”

Pairwork is a housework sharing app for working couples. It supports the sharing of chores by sharing chores and visualizing the person, time, and effort involved.

App Store: https://apps.apple.com/app/id6464381260 

Google Play: https://play.google.com/store/apps/details?id=jp.mediba.pairwork 

mediba operates Japanese carrier-related services such as “Ponta Pass”,”au5G Channel”, and “au Wellness”, and also develops various media-related businesses using mediba’s capabilities such as UX/UI consulting, BPO, and off-shore development.  By providing services that support the environment in which users can access necessary information at any time via the Internet, we are working to realize mediba’s mission “HAPPY” for people.

All company names and product or service names are registered trademarks of their respective companies.

Inquiries regarding this matter
mediba Inc.
Public Relations E-mail: koho@mediba.jp

YolTech Announces First Clinical Data from Ongoing Investigator-Initiated Trial of YOLT-101, An In-Vivo Base Editing Therapy for Familial Hypercholesterolemia

SHANGHAI, April 28, 2025 /PRNewswire/ — YolTech Therapeutics Co.,Ltd, a clinical-stage in vivo gene editing company committed to pioneering the next generation of precision genetic medicines, announced promising interim clinical data from an investigator-initiated trial (IIT) of YOLT-101 (NCT06458010), and the data has been published on medRxiv. YOLT-101 is an investigational in vivo base editing therapy for the treatment of heterozygous familial hypercholesterolemia (HeFH). Clinical data demonstrate that YOLT-101 can safely and effectively reduce low-density lipoprotein cholesterol (LDL-C) levels in HeFH patients with a single administration. As a next-generation gene-editing therapy, YOLT-101 represents a breakthrough in lipid-lowering treatment – moving beyond daily pills and regular injections, and opening a new era of “one-time treatment for lifelong LDL-C reduction.”

YOLT-101 is a next-generation in vivo base-editing therapeutic independently developed by YolTech. It features the novel, proprietary adenine base editor, YolBE—specifically hpABE5—which consists of nCas9 and a newly discovered deaminase derived from Hafnia paralvei. For delivery, it utilizes a new lipid nanoparticle (LNP) formulation. Unlike traditional CRISPR/Cas9 systems that rely on inducing DNA double-strand breaks (DSBs), hpABE5 enables precise single-base editing without generating DSBs, thereby significantly reducing the risks of chromosomal abnormalities and off-target effects. Extensive preclinical studies have demonstrated its excellent genome editing safety profile.

The in vivo base-editing therapy is delivered via intravenous infusion and selectively internalized by hepatocytes, where it induces a precise nucleotide conversion within the PCSK9 gene. This targeted edit disrupts PCSK9 protein expression, leading to enhanced uptake of LDL-C by LDL receptor on hepatocyte surfaces and finally resulting in a marked reduction in plasma LDL-C levels.

Study Design of the IIT

This is an open-label clinical trial conducted in patients with HeFH. The primary objective is to evaluate the safety and tolerability of YOLT-101, while also aiming to explore preliminary efficacy and pharmacodynamics. As of March 15, 2025, a total of 6 subjects have been enrolled: 1 in the 0.2 mg/kg cohort, 2 in the 0.4 mg/kg cohort, and 3 in the 0.6 mg/kg cohort. All subjects have completed at least 24 weeks of safety follow-up, with the longest reaching 36 weeks.

Safety and Tolerability

YOLT-101 has shown good safety and tolerability. As of March 15, 2025, no serious adverse events (SAEs), dose-limiting toxicity (DLT) events, or Grade ≥3 adverse events (according to CTCAE v5.0) were observed in any dose group. All enrolled subjects are under follow-up as scheduled.

The most common treatment-related adverse event was transient infusion-related reactions (5/6, 83.3%), with a manifestation of fever that resolved within 24 hours. Mild elevations in liver enzymes (3/6, 50.0%) were reported, which emerged on Day 4-7 following administration and rapidly alleviated usually after 7 days. All these patients did not show any relevant symptoms, and their plasma bilirubin levels (important indices for liver function) remained within normal limits throughout. No clinically significant changes were observed in other laboratory parameters.

Efficacy and Pharmacodynamics

LDL-C levels demonstrated a dose-dependent reduction following administration. Baseline LDL-C was 4.9 ± 0.6 mmol/L. In the 0.4 mg/kg and 0.6 mg/kg cohorts, sustained reductions in LDL-C were observed as early as Week 1 post-administration, reaching a maximal effect by Week 4. In the 0.6 mg/kg group, mean LDL-C level decreased by around 50% through the last follow-up with acquired data compared to baseline. The subject with the greatest response showed an LDL-C level of approximately 1 mmol/L (maximal percent change from baseline over 74%), and the efficacy has sustained for over 6 months following single-dose infusion. Pharmacodynamic data showed consistent trends, with plasma PCSK9 protein levels decreasing by over 70% from baseline starting at Week 4 in the 0.6 mg/kg group (maximal individual reduction reached 87%).

Notably, all enrolled subjects in this study were HeFH patients. PCSK9-targeting therapies typically show reduced efficacy in this population compared to with general hypercholesterolemic population. This suggests that YOLT-101 may demonstrate even greater lipid-lowering potential in the general hypercholesterolemic population.

In summary, YOLT-101 exhibits favorable safety and tolerability in HeFH patients, with adverse events being mild and transient. Both pharmacodynamic (PCSK9) and efficacy (LDL-C) outcomes in the 0.4 mg/kg and 0.6 mg/kg groups showed durable, dose-dependent reductions. These results support the potential of YOLT-101 to achieve “single-dose, lifelong lipid lowering.”

“We are dedicated to revolutionizing traditional approaches to cardiovascular disease through next-generation base editing technology and groundbreaking single-dose treatment,” said Dr. Yuxuan Wu, co-founder and CEO of YolTech Therapeutics. ” Patients with heterozygous familial hypercholesterolemia (HeFH) suffer from a lifelong, genetically driven impairment in LDL-C metabolism, resulting in markedly elevated low-density lipoprotein cholesterol (LDL-C) levels from birth. This population is at exceptionally high risk for premature atherosclerotic cardiovascular diseases. Current lipid-lowering therapies rely heavily on long-term, continuous administration. However, once treatment is discontinued, LDL-C levels rebound. These regimens are frequently hindered by poor patient adherence and drug intolerance—highlighting a critical unmet need for more durable, patient-friendly therapeutic solutions. Current clinical data of YOLT-101 demonstrates a single YOLT-101 administration can lead to significant and durable reductions in LDL-C levels. By precisely editing key genes regulating LDL-C levels in the liver, YOLT-101 has the potential to be a transformative ‘one-time treatment, lifelong cure’ therapy. We look forward to further confirming its safety and efficacy in larger-scale clinical studies and conferring benefits to patients worldwide.”

About Familial Hypercholesterolemia (FH)

Familial hypercholesterolemia (FH) is caused by mutations in LDL metabolism-related genes (LDLR, APOB, PCSK9). As a result, patients with FH have markedly elevated low-density lipoprotein cholesterol (LDL-C) levels and premature atherosclerotic cardiovascular disease (ASCVD). The global prevalence of FH is 1:200-1:250, affecting a total of ~34 million people worldwide.

Current FH management strategies include lifestyle modifications, lipid-lowering medications, lipoprotein apheresis, and liver transplantation. The standard of treatment involves pharmacotherapy, with most patients receiving a triple regimen of statins, ezetimibe, and PCSK9 inhibitors. However, current therapies have significant limitations including suboptimal efficacy, intolerable side effects, and poor long-term adherence. These challenges underscore the urgent need for novel, durable therapies to address the lifelong treatment burden of FH.

About YolTech

YolTech Therapeutics is a clinical-stage in vivo gene editing company committed to pioneering the next generation of precision genetic medicines. Our approach combines innovative gene editing technologies with an advanced lipid nanoparticle (LNP) delivery system, creating a versatile platform designed to address a wide range of serious diseases. Central to our mission is the development of internal capabilities, including end-to-end manufacturing, to ensure the highest standards of quality and scalability. Our lead candidate, targeting ATTR, marks a significant milestone as China’s first LNP-mediated in vivo gene editing therapy to enter clinical development. With promising early clinical outcomes, YolTech is also advancing therapies for familial hypercholesterolemia (FH) and primary hyperoxaluria type 1 (PH1). As a company dedicated to transforming the treatment landscape, YolTech continues to push the boundaries of what is possible in gene editing.

For more information, please visit: www.yoltx.com

Lost to History: Myanmar Heritage Falls Victim to Quake

This photo taken on April 12, 2025 shows people driving past the debris of a damaged Buddha statue in Inwa on the outskirts of Mandalay, following the devastating March 28 earthquake. (Photo by Sai Aung MAIN / AFP)

When a massive earthquake hit Myanmar last month, centuries of sacred history tumbled down — towering Buddha idols, sky-scraping stupas and the pure-white pagoda where 83-year-old Khin Sein has prayed for most of her life.

Introducing Reversec: Shaping the future of offensive cybersecurity

New company unites decades of experience to deliver consulting services grounded in pioneering research

STOCKHOLM, April 28, 2025 /PRNewswire/ — Reversec launches today as a new name in cybersecurity consulting, dedicated to helping businesses overcome their most complex security challenges. Formerly known as the Consulting unit of WithSecure, Reversec focuses on turning pioneering research into practical solutions that help organizations stay ahead of threats.

With an emphasis on offensive, proactive, strategies, Reversec ensures businesses are prepared to tackle evolving security risks. By combining deep industry experience with a commitment to continuous research, Reversec delivers straightforward and effective services that not only protect but also strengthen its clients’ operations.

Launching Reversec as a new company allows us to focus on being a nimble, research-led cybersecurity consultancy with an aim to redefine offensive security” said Scott Reininga, Executive Vice President of Reversec. “We adopt a hacker mindset, simulating the tactics and strategies used by cybercriminals so we can turn complex security challenges into clear solutions and make cybersecurity a strategic advantage for our clients.”

Reversec unites expertise from leading names in the cybersecurity world, including MWR Infosecurity, F-Secure, WithSecure, nSense, and Inverse Path. With over three decades of combined experience, the team brings unmatched knowledge to help organizations build stronger defenses and reduce risks. Reversec is also committed to openly sharing its expertise with clients and the wider community, encouraging informed decisions about security.

For more details about Reversec, visit www.reversec.com.

About Reversec

At Reversec, we help organizations tackle their most complex cybersecurity challenges. Our offensive-driven consulting services ensure our clients stay ahead of emerging threats.
 
Continuous research is at the core of what we do. We believe true protection comes from investing in pioneering security research and translating those insights into practical, real-world solutions for our customers.
 
We openly share our research and expertise with you, and the wider community, to help make informed decisions about security. Our research findings provide the rationale behind our recommendations, ensuring you understand and trust our approach.
 
Our vision is to be the leading global provider of offensive-driven consulting services. With some of the industry’s brightest minds, we’ve helped organizations worldwide strengthen their defenses and mitigate cyber risks.

Media Contact

Kelly Friend
kelly.friend@reversec.com
+44 (0)7880 488357

James E. Malackowski Recognized with the Highest Honor in Intellectual Property Licensing

The Licensing Executives Society International presents a Gold Medal to Ocean Tomo Co-founder James E. Malackowski.

SINGAPORE and JERICHO, N.Y., April 28, 2025 /PRNewswire/ — J.S. Held announces that the Licensing Executives Society International (LES) has recognized intellectual property expert James E. Malackowski with its highest honor in the business of intellectual property – the LES Gold Medal. Mr. Malackowski was presented with the LES Gold Medal for his exceptional contribution to LESI and the licensing profession during the 2025 LES International Annual Conference in Singapore. He is only the 31st recipient of the LES Gold Medal, first awarded in 1971. 

-

Notably, Mr. Malackowski joins only six others who have received the LES Gold Medal and inclusion in the IP Hall of Fame, a combination generally regarded as the ultimate recognition in the IP services industry. Mr. Malackowski was inducted as the 87th member of the IP Hall of Fame in 2022. 

Others who have been similarly recognized with both such awards are Dudley B. Smith who was instrumental in forming the Licensing Executives Society; Heinz Goddar who is widely regarded as a global IP luminary dedicating his career to advancing the understanding of IP across academia, research, governmental, and commercial enterprises; Thierry Sueur who helped shape IP policy in his role at the International Chamber of Commerce as well as his work as chairman of the IP Committee of the French business federation MEDEF and vice chairman of the board of the French Patent Office; Francis Gurry as the former Director General of the World Intellectual Property Organization (WIPO); Randall R. Rader as former Chief Judge of the United States Court of Appeals for the Federal Circuit; and, Hon. Pauline Newman who was appointed to the United States Court of Appeals for the Federal Circuit in 1984. 

Mr. Malackowski’s latest award follows annual recognition since 2007 by leading industry publications. He has been included as one of the ‘World’s Leading IP Strategists’; listed among “50 Under 45” by IP Law & Business™; included in the National Law Journal’s inaugural list of 50 Intellectual Property Trailblazers & Pioneers; named as one of “The Most Influential People in IP” by Managing Intellectual Property™; selected as 1 of 50 individuals, companies, and institutions that framed the first 50 issues of IAM Magazine; and noted as 1 of 60 leading global Economics Expert Witnesses by the same publication. In 2011, Mr. Malackowski was selected by the World Economic Forum as one of less than twenty members of the Network of Global Agenda Councils to focus on questions of IP policy. In 2013, he was inducted into the Chicago Area Entrepreneurship Hall of Fame by the Institute for Entrepreneurial Studies at the University of Illinois at Chicago College of Business Administration.

Mr. Malackowski is widely known for his work to develop a more efficient and transparent market for IP rights, including oversight for the Ocean Tomo 300® Patent Index, the first large-scale public auction for patents, the framework for the Intellectual Property Exchange International, and the current online market for patent sales—OceanTomoBidAsk.com. Mr. Malackowski has led the publication of the Ocean Tomo Intangible Asset Market Value® study for more than twenty years documenting the transition of global markets from tangible assets to intangible assets driven. Malackowski’s firm continues to update this study, which has been downloaded and cited by third parties on more than 150,000 occasions.

Mr. Malackowski has focused his not-for-profit efforts with organizations leveraging science and innovation to benefit children and students, including those in less developed countries. He served for more than twenty years as a Trustee or Director of the National Inventors Hall of Fame, Inc., an organization providing summer enrichment programs for more than 100,000 students annually. For more than ten years, Mr. Malackowski served as a Director of Chicago’s Stanley Manne Children’s Research Institute, advancing the organization’s agenda to measure and report the impact of its pediatric research.

Mr. Malackowski is a frequent speaker on emerging technology markets and related financial measures. He has addressed mass media audiences, including Bloomberg Morning Call, Bloomberg Evening Market Pulse, Bloomberg Final Word, CNBC Closing Bell, CNBC On the Money, CNBC Street Signs, CNBC World Wide Exchange, CBS News Radio, and Fox Business National Television, as well as other recognized news-based internet video channels.

As an inventor, Mr. Malackowski has twenty issued U.S. patents. He is a frequent instructor for graduate studies on IP management and markets and a Summa Cum Laude graduate of the University of Notre Dame, majoring in accountancy and philosophy. He is a Certified Licensing Professional and a Registered Certified Public Accountant in the State of Illinois.

About Ocean Tomo

Ocean Tomo provides Expert Opinion, Management Consulting, Advisory, and Specialty Technical Services focused on matters involving intellectual property (IP) and other intangible assets. Practice offerings address economic damage calculations and testimony; business licensing strategy and contract interpretation; patent-focused business intelligence; portfolio development strategy; litigation support; trade secret reasonable measures; asset and business valuation; strategy and risk management consulting; merger and acquisition advisory; debt and equity private placement; and IP brokerage.

About J.S. Held

J.S. Held is a global consulting firm that combines technical, scientific, financial, and strategic expertise to advise clients seeking to realize value and mitigate risk. Our professionals serve as trusted advisors to organizations facing high stakes matters demanding urgent attention, staunch integrity, proven experience, clear-cut analysis, and an understanding of both tangible and intangible assets. The firm provides a comprehensive suite of services, products, and data that enable clients to navigate complex, contentious, and often catastrophic situations.

More than 1,500 professionals serve organizations across six continents, including 84% of the Global 200 Law Firms, 75% of the Forbes Top 20 Insurance Companies (90% of the NAIC top 50 Property & Casualty Insurers), and 71% of the Fortune 100 Companies.

Verdantix, in their Green Quadrant: Enterprise Risk Management Consulting Services (2025) report, benchmarks 15 of the most prominent enterprise risk management (ERM) advisors, identifying global consulting firm J.S. Held among the leading companies based on capabilities and momentum.

J.S. Held, its affiliates and subsidiaries are not certified public accounting firm(s) and do not provide audit, attest, or any other public accounting services. J.S. Held, its affiliates and subsidiaries are not law firms and do not provide legal advice. Securities offered through PM Securities, LLC, d/b/a Phoenix IB, a part of J.S. Held, member FINRA/ SIPC, or Ocean Tomo Investment Group, LLC, a part of J.S. Held, member FINRA/ SIPC. All rights reserved.

Kristi L. Stathis | Global Public Relations | +1 786 833 4864 | Kristi.Stathis@jsheld.com

Sonitus Medical and BHM Establish Strategic Cooperation

SHANGHAI, April 28, 2025 /PRNewswire/ — Sonitus Medical has entered into a strategic cooperation with BHM, a renowned European manufacturer of bone conduction hearing devices. The two companies will engage in deep collaboration across product development, manufacturing, regulatory approval, marketing, and sales. Under the agreement, Sonitus Medical grants BHM the commercialization rights outside of China for two innovative bone conduction hearing products developed by Sonitus. BHM, together with its parent company MED-EL, a global leader in implantable hearing solutions, will promote and distribute the products through MED-EL’s extensive marketing network, which spans more than 130 countries.

“The medical-grade bone conduction market for patients with conductive hearing loss, single-sided deafness, and mixed hearing loss is still in its infancy in China, but holds tremendous potential. In China, Sonitus Medical is already the leader in this niche segment. We are dedicated to developing innovative, high-quality, non-invasive bone conduction hearing solutions. Our products undergo rigorous clinical audiology validation and meet world-class standards. An increasing number of hearing-impaired individuals in China rely on Sonitus Medical’s products in their daily lives and work,” said Shawn Pu, Chairman of Sonitus Medical.

“We are very pleased to have reached a strategic cooperation with BHM. BHM is a renowned European company specializing in the research and production of medical-grade bone conduction devices. Its parent company, MED-EL, is a global pioneer and leader in implantable hearing solutions. This strategic cooperation signifies recognition of the Sonitus Medical team’s innovation capabilities by an important partner, and we are truly honored. We firmly believe that Sonitus Medical can bring greater value to our partners through this collaboration, and together, we can provide better products for hearing-impaired people worldwide. We wish this cooperation great success!” said Pu.

 “Even in relatively mature hearing markets like Europe and the United States, there remain many unmet needs among patients with conductive hearing loss, single-sided deafness, and mixed hearing loss. There is still significant growth potential for medical-grade bone conduction hearing devices, especially innovative and high-quality non-invasive solutions. Not long ago, MED-EL, the global leader in implantable hearing solutions, acquired BHM, which signals a strong push in this field,” said Markus Hütter, Managing Director of BHM. “Before this framework agreement, BHM had already established a successful business relationship with Sonitus Medical. We are delighted to move forward into a deeper strategic cooperation. Sonitus Medical is a dynamic and creative team with deep understanding and experience in medical-grade bone conduction. Through our collaboration, we hope to better leverage the efficiency, quality, and cost advantages of the Chinese supply chain, combined with our brand and marketing strengths in global markets—particularly the mature European and American markets—to offer patients newer and better solutions. I believe this is a truly win-win cooperation.”

About Sonitus Medical

Sonitus Medical originates from Silicon Valley in the United States and is now based in the Zhangjiang International Medical Park in Shanghai. The company specializes in the research, development, and manufacturing of medical-grade bone conduction hearing devices that meet international clinical standards, providing innovative hearing solutions for patients around the world. Sonitus Medical holds over 100 global invention patents and ranks among the top in China’s hearing industry. Sonitus Medical is a non-invasive, medical-grade bone conduction expert, offering the most comprehensive range of non-invasive bone conduction hearing solutions currently available on the market. The company pioneered the SoundBite hearing system, the world’s FIRST non-surgical and removable hearing solution that imperceptibly transmits sound via the teeth as bone conduction, which was ranked No.1 on the “Top 10 U.S. Medical Innovations of the Year” by the Cleveland Clinic. This revolutionary system achieves Direct-Drive bone conduction through a non-invasive approach, with clinical hearing outcomes comparable to or even better than surgically implanted bone-anchored hearing aids. Sonitus Medical has developed a variety of high-quality, non-invasive bone conduction hearing solutions for people of all ages with conductive hearing loss, single-sided hearing loss, and mixed hearing loss. These include glasses-style, headband-style, adhesive bone conduction hearing aids, etc. For more information, please visit: www.sonitus.com.

About BHM

BHM – the Berl Hörgeräte Manufaktur – develops high-quality hearing aid systems, carefully manufactured by hand in Austria and distributed around the world. Its core competence – the continual development and precise manufacture of hearing systems and bone conductors – combines craftmanship with high-end technology. As a trailblazer in hearing aids, accessories and precision components for the medical technology field, BHM also produces highly sophisticated micro-components and components for hearing and prosthesis parts. Many years of experience and its commitment to perfectionism make BHM a globally sought-after specialist in bone conduction and special hearing systems. MED-EL acquired BHM in 2024. For more information, please visit: www.bhm-tech.at.

About MED-EL

MED-EL Medical Electronics, a leader in implantable hearing solutions, is driven by a mission to overcome hearing loss as a barrier to communication and quality of life. The Austrian-based, privately owned business was co-founded by industry pioneers Ingeborg and Erwin Hochmair, whose ground-breaking research led to the development of the world’s first micro-electronic multi-channel cochlear implant (CI), which was successfully implanted in 1977 and was the basis for what is known as the modern CI today. This laid the foundation for the successful growth of the company in 1990, when they hired their first employees. To date, MED-EL has more than 2,800 employees from around 80 nations and 30 locations worldwide. The company offers the widest range of implantable and non-implantable solutions to treat all types of hearing loss, enabling people in 137 countries enjoy the gift of hearing with the help of a MED-EL device. MED-EL’s hearing solutions include cochlear and middle ear implant systems, a combined electric acoustic stimulation hearing implant system, auditory brainstem implants as well as surgical and non-surgical bone conduction devices. For more information, please visit: www.medel.com.  

Manulife Launches Two New Critical Illness Plans: IncomeGuard and IncomeShield Offer Market-Leading Annual Critical Illness Payouts for Potential Income Loss During Long-term Treatments

IncomeGuard and IncomeShield introduce a m arket-first[1] heart attack/stroke continuous treatment benefit offering up to 100% coverage[2]for each payout following receipt of a major critical illness benefit, along with total critical illness coverage of up to 1,000% and 500%, respectively, of notional amount

IncomeShield also features s implified underwriting procedures with just three health questions

HONG KONG, April 28, 2025 /PRNewswire/ — Manulife Hong Kong today announced the launch of two new critical illness plans designed to offer customers market-leading annual critical illness payouts, helping to mitigate potential income loss during long-term treatment. The IncomeGuard Critical Illness Protector covers 121 critical illnesses and diseases, providing a market-first[1] heart attack/stroke continuous treatment benefit with up to 100% of the notional amount upon diagnosis of a heart attack or stroke for subsequent specified complex or major surgeries, following the receipt of major critical illness benefit. The IncomeShield Critical Illness Protector delivers focused protection for cancer, heart diseases, and stroke, featuring simplified underwriting with as few as three health questions. Together, these plans provide essential financial support tailored to the diverse needs of customers facing serious health challenges.

Darren Thompson, Chief Product Officer_Manulife Hong Kong and Macau
Darren Thompson, Chief Product Officer_Manulife Hong Kong and Macau

Manulife’s research[3] reveals that consumers seeking critical illness coverage prioritize three key factors: coverage for a wide variety of critical illnesses (53%), the availability of various value-added services to support them during illness (39%), and coverage for recurring critical illnesses (37%). In addition, upon diagnosis, 39% of surveyed consumers identified their immediate concern, ranked among the top three, as losing their ability to work and their income-earning potential. This was closely followed by 34% who cited becoming a burden to their family and needing care as their next most pressing issue. Yet, even as they contemplate securing insurance coverage for critical illnesses, one of their top concerns is the higher premiums that come with increasing age (25%). These findings underscore the importance of financial stability in helping consumers focus on their recovery and providing them with peace of mind.

The IncomeGuard Critical Illness Protector offers extensive coverage for 121 critical illnesses and diseases, including 60 major critical illnesses, 44 early-stage critical illnesses, and 17 juvenile diseases. Key features include:

  • Extra  coverage : Provides up to 100% extra critical illness coverage if the life insured is diagnosed with a major critical illness, an early-stage critical illness and/or juvenile disease, or passes away within the first 10 policy years[4]. This offers annual income support, with coverage of up to 1,000% of the notional amount[5] from diagnosis to  treatment for cancer, heart attack, and stroke. 
  • [Market-first[1] ] Heart attack/stroke continuous treatment benefit: Upon diagnosis of a heart attack or stroke following the receipt of a major critical illness benefit, this feature offers extra protection with each payout of up to 100% of the notional amount for subsequent specified complex or major surgeries.
  • Premium waiver: Premiums for the basic plan are waived for 12 months starting from the premium due date immediately after the diagnosis date of an early-stage critical illness or juvenile disease once benefits are paid. All future premiums for the basic plan are also waived following the diagnosis of a major critical illness after benefits are paid.
  • Traditional Chinese medicine: Offers reimbursement for traditional Chinese medicine related to cancer treatment, supporting the recovery journey.
  • Protection Restore Benefit: This benefit provides the total amount previously paid for an early-stage critical illness and juvenile disease that occurred at least a year ago if the life insured has a major critical illness or passes away before the age of 85, providing the life insured with much-needed financial support.
  • Guaranteed premium: The premium amount remains unchanged throughout the payment period, with terms available for 10, 20, or 25 years.[6]

The IncomeShield Critical Illness Protector is designed for customers seeking focused protection against cancer, heart diseases, and stroke. Key features include:

  • Simplified underwriting: Answer just three health questions, mainly focused on health conditions from the past two years, provided that the insured has not been diagnosed with specified diseases.
  • Steady financial support: This offers annual income support, with coverage of up to 500% of the notional amount[7] from diagnosis to treatment for cancer, heart attack, and stroke.
  • [Market-first[1] ] Heart attack/stroke continuous treatment benefit: Upon diagnosis of a heart attack or stroke following the receipt of a major critical illness benefit, this feature offers extra protection with each payout of up to 100% of the notional amount for subsequent specified complex or major surgeries.
  • Late-stage Cancer Advanced Benefit: Provides a one-time advanced payout equal to 100% of the notional amount upon diagnosis of late-stage cancer.[8]
  • Premium waiver: All future premiums for the basic plan are waived after the diagnosis date of a major critical illness, once benefits are paid.
  • Protection Restore Benefit: This benefit provides the total amount previously paid for an early-stage critical illness that occurred at least a year ago if the life insured has a major critical illness or passes away before the age of 85, providing the life insured with much-needed financial support.
  • Guaranteed premium: The premium amount remains unchanged throughout the payment period, with terms available for 10, 20, or 25 years.[6]

Darren Thompson, Chief Product Officer, Manulife Hong Kong and Macau, said: “With rising medical costs and the financial burden of critical illnesses, it is essential for Manulife to offer our customers accessible and holistic insurance solutions that protect themselves and their loved ones during challenging times. While many consumers view critical illness plans as a means to cover treatment expenses, they also serve as a vital income replacement tool. When diagnosed with a critical illness, people often need to take time off for treatment and recovery, leading to significant income loss. This makes critical illness plans invaluable in providing financial stability, allowing individuals to focus on their treatment and recovery journey.”

To provide better support for customers diagnosed with cancer, Manulife’s CancerCompanion Service[9], is now available as a value-added service through a Healthcare Hotline Team and Personalized Medical Case Managers[10], who are qualified nurses with extensive healthcare experience, to guide customers diagnosed with cancer through treatment and recovery. The services feature the industry-leading[11] Cancer Drug Support Service[12], which includes limousine service in collaboration with Prosper Health and Shenzhen New Frontier United Family Hospital, as well as a second medical opinion service to be provided by specialists at Gleneagles Hospital Hong Kong, HKSH Medical Group, CUHK Medical Centre, and all United Family Hospitals. Additionally, discounted cancer check-up packages and dietitian services are available through selected medical service providers[13],[14].

 Terms and conditions apply. For more details and risks about IncomeGuard and IncomeShield, please click on the provided links to access the respective product leaflets.

The content of this press release does not contain the full terms of the policy(ies), and the full terms can be found in the corresponding policy document(s). Before making a purchase, customers are encouraged to read the policy provisions for the exact terms and conditions that apply to these products.


[1] Based on comparisons with other publicly available critical illness plans issued by Hong Kong’s major life insurance companies for individual customers as of April 27, 2025.

[2] For heart attack/stroke continuous treatment benefit, the total amount payable is up to 400% of the notional amount.

[3] Manulife conducted an online survey in December 2024 to gather insights into the needs and preferences of Hong Kong consumers regarding critical illness products. The survey sampled 501 adults aged 25 to 54 with a monthly household income of HK$30,000 or above in Hong Kong.

[4] If the life insured is diagnosed with a major critical illness, the IncomeGuard Critical Illness Protector will pay an additional payout equal to 100% of the major critical illness benefit (excluding any terminal bonus) and any protection restore benefit paid. If the life insured is diagnosed with an early-stage critical illness and/or juvenile disease, the IncomeGuard Critical Illness Protector will pay an additional payout equal to 100% of the amount of the benefit paid for that illness and/or disease. 

[5] Benefit payouts of up to 1,000% of the notional amount include: (1) major critical illness benefit, (2) cancer diagnosis benefit, (3) cancer continuous treatment benefit, (4) heart attack /stroke continuous care benefit, and (5) heart attack /stroke continuous treatment benefit.

[6] It is guaranteed that the basic plan premiums for the initial basic plan notional amount remain unchanged throughout the premium payment period. However, the premium and guaranteed cash value due to an increase in the basic plan notional amount, including those increases triggered by using the inflation protector option, are not guaranteed.

[7] Benefit payouts of up to 500% of the notional amount include: (1) major critical illness benefit, (2) late-stage cancer advanced benefit, (3) cancer diagnosis benefit, (4) cancer continuous treatment benefit, (5) heart attack /stroke continuous care benefit, and (6) heart attack /stroke continuous treatment benefit.

[8] If the late-stage cancer advanced benefit has been paid, the total payable amount of the cancer continuous treatment benefit will be reduced by 100% of the notional amount.

[9] The services covered by the CancerCompanion Service are administrative arrangements and are not part of the product features. For the avoidance of doubt, the use of the service does not imply any expenses or diagnoses associated with the service are covered in the insurance policy(ies). Manulife reserves the right to change designated medical services provider(s) for each service from time to time, or revise or terminate these services at any time without prior notice. Manulife and its insurance advisors do not have relevant licenses and/or qualifications to provide medical services. Medical service providers are independent contractors and are not employees, agent, or servants of Manulife. Manulife shall not be responsible and/or liable for any services, diagnosis, advice or treatment or other acts or omissions of medical service providers. Manulife shall not be liable for any acts or omission of any other service providers. Unless otherwise specified, all related expenses (such as costs arising from medication, consultations, examinations, tests, etc.) will be borne and paid by the customer. Please note that some of these services are only available to insured persons located in designated regions only (e.g. Hong Kong); please refer to the relevant terms and conditions for details. The CancerCompanion Service is subject to terms and conditions, so please refer to the relevant leaflet for details.

[10] The service is supportive in nature and does not provide diagnosis, treatment or medical advice. The information provided is not medical advice or recommendation. It should not be relied upon by users in their decision making in relation to their medical conditions. If you need any medical care or emergency medical service, please visit a doctor for consultation immediately. The Healthcare Hotline Team service is subject to terms and conditions; please refer to the Holistic “Medical Professional Support Service” leaflet for details.

[11] “Industry-leading” is based on comparisons of the administrative services with other publicly available critical illness plans offered by Hong Kong’s major life insurance companies for individual customers as of March 19, 2025.

[12] Eligibility applies to the Insured of ManuLove Care, ManuPrimo Care/ManuPrimo Care (BestStart), ManuBright Care 2 Plus, ManuBright Care 2, Manulife Bright Care PRO, ManuVital Care, Manulife Supreme VHIS Flexi Plan, Manulife Supreme Lite VHIS Supplementary Benefit, Manulife Supreme Medical Plan, Manulife Supreme Lite Medical Supplementary Benefit, ManuMaster Healthcare Series/Benefits, ManuShine Healthcare Series/Benefits, Manulife First VHIS Flexi Plan, Manulife Shelter VHIS Standard Plan, ManuGuard Medical Plan/Benefit, Cancer Treatment Benefit, ManuEnrich Medical Top-up Plan, IncomeGuard and IncomeShield. The eligible policy(ies) must be without relevant exclusion(s). To be eligible for Cancer Drug Support Service, the Insured must be confirmed with cancer and the respective diagnosis(es) must be supported by a registered medical practitioner. Each eligible Insured can receive at most one Cancer Drug Support Service per life regardless of the number of eligible policies they are insured. Terms and conditions apply.

[13] These services are provided by Manulife’s partnered medical service providers which are not agents of Manulife and do not act on behalf of Manulife. Manulife’s services are supportive in nature and Manulife shall not be responsible or liable for any diagnosis, advice, or treatment or other acts or omissions of medical service providers. Manulife shall not be liable for any acts or omissions of any other service providers.

[14] The arrangement of the services and discount provided by Manulife’s partnered medical service providers may change from time to time without prior notice. The services and discounts are subject to the terms and conditions imposed by Manulife’s partnered medical service providers.

About Manulife Hong Kong

Manulife Hong Kong has been a trusted name for more than 125 years. Since our operations started in Asia in 1897, we have grown to become one of the top-tier providers of financial services, offering a diverse range of protection and wealth products and services to over 2.6 million customers in Hong Kong and Macau. We are committed to helping make decisions easier and lives better for our customers.

Manulife Hong Kong, through Manulife International Holdings Limited, owns Manulife (International) Limited, Manulife Investment Management (Hong Kong) Limited, and Manulife Provident Funds Trust Company Limited. These entities are all subsidiaries of Manulife Financial Corporation.

About Manulife

Manulife Financial Corporation is a leading international financial services provider, helping our customers make their decisions easier and lives better. With our global headquarters in Toronto, Canada, we operate as Manulife across Canada, Asia, and Europe, and primarily as John Hancock in the United States, providing financial advice and insurance for individuals, groups and businesses. Through Manulife Wealth & Asset Management, we offer global investment, financial advice, and retirement plan services to individuals, institutions, and retirement plan members worldwide. At the end of 2024, we had more than 37,000 employees, over 109,000 agents, and thousands of distribution partners, serving over 36 million customers. We trade as ‘MFC’ on the Toronto, New York, and the Philippine stock exchanges, and under ‘945’ in Hong Kong.

Not all offerings are available in all jurisdictions. For additional information, please visit manulife.com.